Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma

Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorMayo Clinic

About this trial

This phase II trial compares the safety, side effects and effectiveness of reduced dose radiation therapy to standard of care dose radiation in treating patients with indolent non-Hodgkin lymphoma. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Standard of care radiation treatment for indolent non-Hodgkin lymphoma is usually delivered in 12 treatments. Studies have shown indolent lymphoma to be sensitive to radiation treatment, however, larger doses have higher rates of toxicities. A reduced radiation dose may be safe, tolerable and/or effective compared to standard of care radiation dose in treating patients with indolent non-Hodgkin lymphoma.

Eligibility criteria

Qualifiers

Age ≥ 18 years

Follicular lymphoma (grade 1 or 2 or 3A)

Marginal zone lymphoma (nodal or extranodal)

Follicle center lymphoma

Disqualifiers

Pregnant women

Nursing women

Women of childbearing potential who are unwilling to employ adequate contraception

T-cell lymphoma

Trial design

Treatments tested in this trial

  • Computed Tomography
  • Endoscopic Procedure
  • Involved-site Radiation Therapy (3 Fractions)
  • Involved-site Radiation Therapy (12 Fractions)
  • Positron Emission Tomography
  • Questionnaire Administration

Treatment groups

112 Participants
are divided into 2 treatment groups

Sponsors and collaborators